Order Article Reprints

Shivapurkar N, Gay MD, He A, Chen W, Golnazar S, Cao H, Duka T, Kallakury B, Vasudevan S, Smith JP. Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023; 24(4):3625. https://doi.org/10.3390/ijms24043625

Shivapurkar, Narayan, Martha D. Gay, Aiwu (Ruth) He, Wenqiang Chen, Shermineh Golnazar, Hong Cao, Tetyana Duka, Bhaskar Kallakury, Sona Vasudevan, and Jill P. Smith. 2023. "Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma" International Journal of Molecular Sciences 24, no. 4: 3625. https://doi.org/10.3390/ijms24043625

Shivapurkar, N., Gay, M. D., He, A., Chen, W., Golnazar, S., Cao, H., Duka, T., Kallakury, B., Vasudevan, S., & Smith, J. P. (2023). Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 24(4), 3625. https://doi.org/10.3390/ijms24043625